Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease
Bioconjugation Insights · 2025
DOI: 10.18609/bci.2025.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Helen Bright. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Early engagement with regulatory bodies is essential to clarify how peptide conjugates will be evaluated.” Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks to Helen Bright, CSO, Centauri Therapeutics, about an immune-stimulating platform that leverages peptide conjugation to enhance immune responses. She discusses the challenges and advantages of this conjugate platform, from achieving regulatory body approval to therapeutic efficacy. Bioconjugation Insights is the only digital content channel that truly provides the ‘big picture’ for this rapidly evolving and expanding field. If you would like to access all of our Open Access content, you can register here.
Zitieren
APA
Bright, H. (2025). Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.003
Vancouver
Bright H. Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.003
BibTeX
@article{Bright2025,
author = {Bright, Helen},
title = {Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease},
journal = {Bioconjugation Insights},
year = {2025},
doi = {10.18609/bci.2025.003}
}
EUVIMED